AQUIPTA®
(Atogepant)
ABBVIE
HK Reg. No. HK-68287 (03 Jul, 2024) & HK-68288 (03 Jul, 2024)
Composition:1
Aquipta® (Atogepant) is an orally administered, small molecule, selective calcitonin gene-related peptide (CGRP) receptor
antagonist that blocks the binding of the CGRP to the receptor and antagonizes CGRP receptor function. CGRP is a
neuropeptide that has been associated with migraine pathophysiology. It is available in 10 mg and 60 mg tablet forms.
Indication:1
Aquipta® (Atogepant) tablet is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.
References
1. AQUIPTA® (atogepant) EU Summary of Product Characteristics. August 2023. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/aquipta. Accessed November 2023.
2. Anagrelide Sandoz 0.5 mg hard capsule - Summary of Product Characteristics (SmPC) - (emc). https://www.medicines.org.uk/emc/product/10094/smpc#gref. 3. Amorolfine 5% w/v
Medicated Nail Lacquer (Legal category P) - Summary of Product Characteristics (SmPC) - (emc). https://www.medicines.org.uk/emc/product/7414/smpc#gref
